Abstract
Purchase PDF (134 K)
E-mail Article
Add to my Quick Links
Cited By in Scopus (3)
doi:10.1016/j.cca.2006.02.033 
Copyright © 2006 Elsevier B.V. All rights reserved.
The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients
Received 13 December 2005;
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
Background
In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls. Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values. Moreover, we defined the receiver-operating characteristics (ROC) curve for M-CSF and CA 15-3, and correlation between both parameters.
Methods
M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects. M-CSF was determined using enzyme-linked immunosorbent assay (ELISA). CA 15-3 was measured using a microparticle enzyme immunoassay kit (MEIA).
Results
There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group. The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage. Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels. The M-CSF and CA 15-3 diagnostic specificities were 95%. The diagnostic sensitivity (59%), the positive predictive value (97%) and the negative predictive value (41%) were higher for M-CSF than for CA 15-3 (48.8%, 95% and 40.1%, respectively). The combined use of both cytokines resulted in the increase of the sensitivity to the range of 70%. We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage. The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).
Conclusions
These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
Keywords: Breast cancer; CA 15-3; HGFs; M-CSF; Tumor markers
Statistical significance compared to the control group.